Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review].

Franco D, Henao Y, Monsalve M, Gutiérrez F, Hincapie J, Amariles P.

Farm Hosp. 2013 Nov-Dec;37(6):539-57. doi: 10.7399/FH.2013.37.6.1077. Review. Spanish.

2.

[Rhabdomyolysis induced by statins].

Hamano T, Muto T, Kuriyama M.

Nihon Naika Gakkai Zasshi. 2007 Aug 10;96(8):1646-51. Review. Japanese. No abstract available.

PMID:
17802715
3.

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

Psaty BM, Furberg CD, Ray WA, Weiss NS.

JAMA. 2004 Dec 1;292(21):2622-31. Epub 2004 Nov 22. Review.

PMID:
15572720
4.

Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.

Zhou YT, Yu LS, Zeng S, Huang YW, Xu HM, Zhou Q.

Ther Clin Risk Manag. 2014;10:17-26. doi: 10.2147/TCRM.S55512. Epub 2013 Dec 20. Review.

5.

Statin safety and drug interactions: clinical implications.

Bottorff MB.

Am J Cardiol. 2006 Apr 17;97(8A):27C-31C. Epub 2006 Jan 25. Review.

PMID:
16581325
6.

HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.

Beaird SL.

J Am Pharm Assoc (Wash). 2000 Sep-Oct;40(5):637-44. Review.

PMID:
11029845
7.

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2006 Dec;80(6):565-81. Review.

PMID:
17178259
8.

The statins: drug interactions of significance to the dental practitioner.

Stevenson H, Longman LP, Randall C, Field EA.

Dent Update. 2006 Jan-Feb;33(1):14-6, 18, 20.

PMID:
16512094
9.

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Williams D, Feely J.

Clin Pharmacokinet. 2002;41(5):343-70. Review.

PMID:
12036392
10.

Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?

Martin J, Krum H.

Drug Saf. 2003;26(1):13-21. Review. Erratum in: Drug Saf. 2003;26(12):893.

PMID:
12495360
11.

[Drug-induced myopathies].

Ando H, Fujimura A.

Nihon Rinsho. 2007 Oct 28;65 Suppl 8:390-3. Review. Japanese. No abstract available.

PMID:
18074569
12.

Does simvastatin cause more myotoxicity compared with other statins?

Backes JM, Howard PA, Ruisinger JF, Moriarty PM.

Ann Pharmacother. 2009 Dec;43(12):2012-20. doi: 10.1345/aph.1M410. Epub 2009 Nov 17. Review.

PMID:
19920157
13.

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R.

JAMA. 2004 Dec 1;292(21):2585-90. Epub 2004 Nov 22.

PMID:
15572716
14.

The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.

Worz CR, Bottorff M.

Expert Opin Pharmacother. 2001 Jul;2(7):1119-27. Review.

PMID:
11583063
15.

Rhabdomyolysis and lipid-lowering drugs.

Tenenbaum A, Fisman EZ, Motro M.

JAMA. 2005 Mar 23;293(12):1448; author reply 1448-9. No abstract available.

PMID:
15784863
16.

[Metabolic interactions with statins].

Molden E, Asberg A.

Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93. Review. Norwegian.

PMID:
11475198
17.

Rhabdomyolysis in association with simvastatin and amiodarone.

Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG.

Ann Pharmacother. 2004 Jun;38(6):978-81. Epub 2004 Apr 6.

PMID:
15069169
18.

Drug-drug interactions and statin therapy.

Trifiro G.

South Med J. 2006 Dec;99(12):1325-6. No abstract available.

PMID:
17233186
19.

Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".

Piorkowski JD Jr.

JAMA. 2004 Dec 1;292(21):2655-7; discussion 2658-9. Epub 2004 Nov 22. No abstract available.

PMID:
15572725
20.

Rhabdomyolysis and HMG-CoA reductase inhibitors.

Omar MA, Wilson JP, Cox TS.

Ann Pharmacother. 2001 Sep;35(9):1096-107. Review. Erratum in: Ann Pharmacother 2001 Oct;35(10):1296.

PMID:
11573861
Items per page

Supplemental Content

Write to the Help Desk